Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. Thank you for joining us and welcome to the Krenetics Pharmaceuticals first quarter 2026 financial results. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Gayatri Dwarkar, Head of Investor Relations. Gayatri, please go ahead. Thank you, operator. Good afternoon, everyone. And thank you for joining us. Thank you, operator. Good afternoon, everyone. And thank you for joining us to discuss the first quarter 2026 results. Today on the call, we have Dr. Scott Struthers, founder and chief executive officer, Isabel Califonos, chief commercial officer, Dr. Alan Krasner, chief endocrinologist, and Toby Schilke, chief financial officer. Please note there's a slide deck for today's presentation, which is in the events and presentation section of the investors page on the Krenetics website. In addition, a press release was issued earlier today and is also available on the corporate website. Slide two. As a reminder, we'll be making forward-looking statements, and I invite you to learn more about the risks and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and certainties associated with the company's business. In particular, today we will be reviewing launch progress to date, our commercialization plans, future performance, and other data about the acromegaly market, which are all necessarily subject to a high degree of uncertainty and risk. These forward...